Hyun Kim
Senior Vice President, Clinical Development AOBiome
Seminars
Thursday 5th November 2026
Investor Panel: Where Is Dermatology Investment Heading Beyond the Dupixent Era?
4:30 pm
- Assessing which indications offer the greatest unmet need and commercial opportunity, guiding portfolio prioritisation, to maximize long-term value creation
- Debating whether the next wave of investment will favour multispecifics, degraders, microbiome therapeutics, AI-designed biologics or engineered-cell approaches, clarifying emerging platform trends, to understand where capital is flowing
- Understanding how investors evaluate differentiation across efficacy, safety, dosing and translational confidence, aligning development strategy with market expectations, to build fundable and partnerable dermatology assets
